The plant will resume production of its COVID-19 vaccine in a matter of months, the paper reported. The company is also working to enlist other facilities to help produce the vaccine, but they are either currently not operational or haven’t received regulatory approval.
While the J&J vaccine has failed to find widespread use in wealthy countries, it remains popular in portions of the developing world, including much of Africa. The vaccine has less-demanding storage requirements than the first generation of mRNA vaccines and offers robust protection against a range of variants when administered as a two-dose series.
Get the full story from our sister site, Pharmaceutical Processing World.